{"title": "ASH: Johnson & Johnson, AbbVie's Imbruvica steals the CLL spotlight with phase 3 study wins", "author": "Carly Helfand", "url": "https://www.fiercepharma.com/pharma/ash-j-j-abbvie-s-imbruvica-steals-cll-spotlight-ph3-study-wins", "hostname": "fiercepharma.com", "description": "SAN DIEGO\u2014Johnson & Johnson and AbbVie's Imbruvica already competes in previously untreated chronic lymphocytic leukemia (CLL). | Johnson & Johnson and AbbVie's Imbruvica already competes in previously untreated chronic lymphocytic leukemia (CLL). But with some new head-to-head data against a \"gold standard\" regimen, the partners are looking to own it.", "sitename": "FiercePharma", "date": "2018-12-04", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}